ClinicalTrials.gg

Program

florzolotau F-18

Also written as “[18F]-APN-1607” and “[18F]APN-1607”.

Its studies are mostly in Alzheimer Disease, led by 3 companies.

Furthest: phase 3, since Jan 29, 20264 company-led studies, 3 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
JYAMS PET Research & Development22 open or runningphase 3since Jan 29, 2026Jan 29, 2026Dec 1, 2026phase 3 · NCT07422857
APRINOIA Therapeutics10 open or runningphase 3since Jan 24, 2022Jan 24, 2022none ahead
APRINOIA Therapeutics11 open or runningphase 2since Oct 17, 2019Oct 17, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2019First study: phase 2 study in Alzheimer DiseaseNew to APRINOIA TherapeuticsAPRINOIA Therapeutics · NCT04141150 · 130 enrolled · United States
  2. Jan 24, 2022APRINOIA Therapeutics’ first study: phase 3 study in Alzheimer DiseaseNew to APRINOIA TherapeuticsAPRINOIA Therapeutics · NCT05542953 · 230 enrolled · China
  3. Jan 29, 2026JYAMS PET Research & Development’s first study: phase 3 study in Alzheimer DiseaseNew to JYAMS PET Research & DevelopmentJYAMS PET Research & Development · NCT07422857 · 316 planned · China
  4. Jul 29, 2026Phase 3 study in Alzheimer DiseaseJYAMS PET Research & Development · NCT07752784 · 12 planned · China

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Alzheimer DiseaseJYAMS PET Research & Development · NCT07422857
  2. Apr 30, 2027Primary completion: phase 3 study in Alzheimer DiseaseJYAMS PET Research & Development · NCT07752784

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07752784Alzheimer Disease · China3RecruitingJYAMS PET Research & DevelopmentApr 30, 202712
NCT07422857Alzheimer Disease · China3RecruitingJYAMS PET Research & DevelopmentDec 1, 2026316
NCT05542953Alzheimer Disease · China3CompletedAPRINOIA TherapeuticsDec 25, 2023230
NCT04141150Alzheimer Disease · United States2Active, not recruitingAPRINOIA TherapeuticsSep 2024130

How it is read

Names in the registry

  • “[18F]-APN-1607”, 2 entries
  • “[18F]APN-1607”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.